Hinge Health shares climbed 11.6% in mid-day trading after the digital musculoskeletal care provider posted a broad-based beat in its Q2 2026 financial results and raised forward guidance.
The company reported quarterly revenue of $212.8 million, a 53% increase from the prior year, while non-GAAP diluted earnings per share came in at $0.59. That EPS result substantially exceeded the Wall Street consensus of $0.13. Hinge Health also delivered a marked improvement in free cash flow, which more than tripled year-over-year to roughly $100 million, implying a free cash flow margin of 47% versus 23% in Q2 2025.
Management updated its full-year 2026 revenue outlook to a range of $818 million to $824 million and provided third-quarter revenue guidance between $223 million and $225 million. Both the full-year and Q3 targets sit comfortably above analysts' prior expectations; the Q3 range notably exceeds the roughly $211 million analyst consensus.
In conjunction with the earnings release, Hinge Health announced a definitive agreement to buy Cylinder Health, a virtual-first digestive healthcare company, for $105 million in cash. The transaction is expected to close in Q3 2026 and is intended to support the launch of a gastrointestinal care program in 2027.
Analysts reacted quickly to the results and the strategic acquisition. Citizens JMP increased its price target to $107 from $96 while maintaining a Market Outperform rating. Needham raised its target to $97 from $76 and kept a Buy rating, and KeyBanc lifted its target to $125 from $90 while retaining an Overweight rating. The combination of a sizeable earnings surprise, higher-than-expected guidance, an acquisition expanding Hinge Health’s clinical footprint, and multiple analyst upgrades helped drive one of the company's most pronounced single-session moves since its IPO.
The broader market provided a supportive backdrop for Hinge Health's rally. The S&P 500 opened higher, building on a record close the previous trading day, with the Dow Jones Industrial Average up 0.8% and the S&P 500 modestly higher in mid-day trading. The positive tone in markets was underpinned by a strong earnings season, where nearly 90% of reporting companies beat estimates, and by optimism about possible progress in U.S.-Iran negotiations that had helped ease oil prices over the prior two sessions.
Following the release, Hinge Health shares traded within striking distance of their 52-week high of $91.50, reflecting investor enthusiasm for the company’s near-term growth outlook and the cash-flow improvement reported for the quarter.
Bottom line: Hinge Health’s Q2 performance and management’s raised guidance, coupled with a strategic acquisition and subsequent analyst upgrades, produced a strong positive market reaction and moved the stock closer to its yearly high.